Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide1The...
-
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to...
-
Weiterentwicklung der Onkologie-Pipeline vorangetrieben mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme: Immunmodulator-Kandidat BNT327, ein gegen PD-L1 und VEGF-A1...
-
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA...
-
Mainz, Deutschland, 5. Mai 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ramón Zapata-Gomez mit Wirkung zum 1. Juli...
-
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management...
-
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing...
-
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
-
New York, USA, April 30, 2025 (GLOBE NEWSWIRE) -- Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight In recent years, the...
-
Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4 Phesgo...